By three-week treatment, dtEVs containing TP53-mRNA and siKRASG12D (dtEVs: 1 × 1011/100 μl, i.p. injection, three-time/week with ~2 × 1011 copies or ~0.3 μg mass of TP53 mRNA and ~5 x 1013 copies or ~0.8 μg mass of siKRASG12D per injection) greatly inhibited the large tumor growth, while combining a low dose of GEM (20 mg/kg, once/week) could further suppress the tumor activity (Fig. 7d,e). This evidence concerns the gene TP53 and neoplasm.